Sensible Medical Innovations

Company Overview

Snapshot

Founded in June 2007 by Amir Ronen, Amir Saroka, Shlomi Bergida, Nadav Mizrahi, and Dan Rappaport, Sensible Medical Innovations operates with 11–50 employees. The company has raised $37.56 million across five funding rounds from four investors. In September 2025, its ReDS™ Pro System was contracted for inclusion in the Federal Supply Schedule (FSS), making it available to VA medical facilities in the US.

Business overview

Sensible Medical Innovations develops and commercializes the ReDS medical radar technology, which originated from defense industry applications for seeing through walls. The company's core product, the ReDS system, is designed for noninvasive monitoring and management of patients with fluid management problems, particularly those living with heart failure (HF), taking diuretic medication, or recovering from coronary artery disease-related events. Serving healthcare providers in hospitals, hospital-type facilities, and home environments, Sensible Medical Innovations operates within the Health Tech & Life Sciences sector, focusing on digital healthcare, patient remote monitoring, and medical devices.

Strategic signal

In September 2025, Sensible Medical Innovations achieved a significant milestone by securing a contract for its ReDS™. This development makes the ReDS system available to VA medical facilities across the US, signaling strong market validation and a substantial expansion opportunity within the federal healthcare system. For investors, this indicates a clear pathway to increased adoption and revenue, particularly within a critical and large-scale patient demographic.

Company Intelligence Q&A

What is Sensible Medical Innovations' primary technology?

Sensible Medical Innovations' primary technology is the ReDS medical radar, which enables noninvasive monitoring of lung fluid. This technology originated from defense industry applications for 'see-through-walls' capabilities.

What was a key market expansion for Sensible Medical Innovations in 2025?

In September 2025, Sensible Medical Innovations' ReDS™ Pro System was contracted for inclusion in the Federal Supply Schedule (FSS), making it available to VA medical facilities in the US.

When did Sensible Medical Innovations license its ReDS technology to Bayer?

Sensible Medical Innovations licensed its ReDS™ technology to Bayer in May 2019.

What was a notable investment in Sensible Medical Innovations in 2019?

In January 2019, Medicure Inc. invested in Sensible Medical Innovations to market the ReDS system.

When did Sensible Medical Innovations receive FDA clearance for its monitor?

Sensible Medical Innovations received FDA 510K clearance for its non-invasive thoracic fluid status monitor in August 2015.